Hyderabad’s RNA Foundry Develops Personalised Cancer Vaccines

The CSR Journal Magazine

The concept of personalised cancer vaccines involves creating a vaccine tailored specifically for an individual patient’s tumour, rather than a generalised treatment for a wider population. This innovative approach is being explored by the Hyderabad-based biotechnology firm PopVax, which has established its RNA Foundry. Launched in October 2026, this facility focuses on the research, development, and manufacturing of personalised mRNA cancer vaccines, aiming to revolutionise cancer treatment.

Unlike traditional vaccines, which are designed for broader demographics, personalised cancer vaccines are crafted based on the unique mutations present in a patient’s cancer cells. The goal is to enhance the immune system’s ability to identify and combat cancer cells that exhibit these abnormal markers.

Mechanism of Action for Personalised Cancer Vaccines

Cancer arises when cells undergo genetic alterations that enable them to proliferate uncontrollably. These alterations can lead to the production of unique proteins, known as neoantigens, which help differentiate cancer cells from healthy ones. Personalised cancer vaccines leverage information from a patient’s tumour to pinpoint these potential targets.

In the context of mRNA vaccines, scientists formulate genetic instructions that prompt the body’s cells to generate specific tumour-associated targets. This process enables the immune system to recognise these targets and mobilise immune cells, particularly T-cells, to attack the cancer cells that display them.

Dr Rahul Thakur, a Consultant Radiation Oncologist at TGH ONCO LIFE Cancer Centre, emphasised that these vaccines are designed to train the immune system to identify and respond to cancerous cells effectively. While this method aims to provide a more targeted cancer treatment, simply identifying potential targets does not guarantee that the immune system will successfully eradicate the cancer.

Current Status and Future Prospects

The interest in personalised cancer vaccines has surged, particularly following clinical studies involving mRNA-based therapies. A notable collaboration between pharmaceutical companies Moderna and Merck has been investigating a personalised mRNA cancer vaccine, intismeran autogene, in conjunction with pembrolizumab (Keytruda) for patients with high-risk melanoma.

Results from a Phase 3 trial in 2026 indicated a two-year recurrence-free survival rate of 82.2 per cent for patients receiving the vaccine alongside pembrolizumab, compared to 70 per cent for those receiving pembrolizumab alone. These findings provide promising evidence for the efficacy of this approach; however, they pertain to a specific cancer type and patient group.

Thus, they cannot be generalised to all personalised cancer vaccines. Dr Thakur noted that while the evidence is developing, further extensive clinical trials are necessary to establish these vaccines as standard treatments. PopVax’s RNA Foundry represents a significant advancement in India’s biotechnology sector, aiming to provide personalised cancer vaccines.

The estimated cost for designing and manufacturing such a vaccine is around $300,000, or approximately Rs 2.5 crore, with a typical timeframe of eight to ten weeks for completion. However, these vaccines are still in the experimental stage and have not yet been administered to patients.

Considerations for Patients

As interest in personalised cancer treatments increases, patients may feel compelled to explore these innovative options. However, experts advise caution, emphasising that these experimental vaccines should not replace established cancer therapies. Dr Thakur highlighted the importance of evaluating a patient’s cancer type, stage, and existing treatment options before considering a personalised vaccine.

Patients must be aware that the effectiveness of these vaccines is not guaranteed and that potential side effects may include fever, fatigue, and injection-site reactions. It is crucial for patients to engage in discussions with their oncologists regarding the risks, benefits, and regulatory status of any experimental treatments they are considering.

Personalised cancer vaccines represent a promising avenue in cancer research, yet they remain an emerging field rather than a substitute for conventional cancer care. The journey from laboratory innovation to validated treatment is complex and requires further exploration.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store – https://apps.apple.com/in/app/newspin/id6746449540

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share

Latest News

Popular Videos